Erasca, Inc. (ERAS) Financials
ERAS Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 461.2 million | 67.7 million |
| Dec. 31, 2025 | 396.2 million | 71.0 million |
| Sept. 30, 2025 | 420.4 million | 72.5 million |
| June 30, 2025 | 445.4 million | 73.1 million |
ERAS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -27.4 million | 8.5 million |
| Dec. 31, 2025 | -21.7 million | 5.8 million |
| Sept. 30, 2025 | -21.7 million | 6.0 million |
| June 30, 2025 | -20.6 million | 6.4 million |
ERAS Net Income
No data available :(
ERAS Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 243.8 million | - | 40.7 million |
| Dec. 31, 2025 | 276.1 million | - | 42.1 million |
| Sept. 30, 2025 | 288.4 million | - | 43.4 million |
| June 30, 2025 | 300.7 million | - | 44.7 million |
ERAS Shares Outstanding
ERAS Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 36000 | 27.3 million | 10.6 million | - |
| Dec. 31, 2025 | 9000 | 23.2 million | 9.4 million | - |
| Sept. 30, 2025 | 6000 | 22.5 million | 10.1 million | - |
| June 30, 2025 | 30000 | 21.2 million | 9.5 million | - |
ERAS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | - | 723000 |
| Dec. 31, 2025 | - | 743000 |
| Sept. 30, 2025 | - | - |
| June 30, 2025 | - | 787000 |
ERAS
Price: $14.43
52 week price:
Earnings Per Share: -0.93 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 393750
Market Capitalization: 4.2 billion